Target Therapeutics (US) gets 510(k) for intracranial coil:
This article was originally published in Clinica
Executive Summary
Target Therapeutics (US) has received FDA clearance to market the Guglielmi detachable coil for intracranial aneurysms. The soft platinum alloy microcoil is intended for use in inoperable or surgical high-risk stroke patients. The coil is delivered using Target's Tracker microcatheter and released electrically. Nearly 40,000 intracranial aneurysms are diagnosed in the US every year and about 25% of these are deemed either inoperable or high-risk for surgical repair.